Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CK1 Inhibitor
Casein kinase 1δ-IN-28 is a selective inhibitor of Casein Kinase 1 (CK1) with an IC50 of 0.0146 μM. This compound demonstrates significant potential for modulating CK1-mediated pathways, making it a valuable tool for studies in cell signaling and cancer research. Additionally, Casein kinase 1δ-IN-28 shows a metabolite rate of 52% in human liver microsomes, indicating its metabolic stability for in vitro applications. -
Casein Kinase Inhibitor
PF-670462 is a selective inhibitor of Casein Kinase I ε/δ, known for its role in modulating circadian rhythms. This compound effectively influences the timing and progression of these rhythms, making it a valuable tool for research into circadian biology and related disorders. Its specificity and potency allow for detailed studies on the regulation of circadian-controlled processes. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-15 is a potent inhibitor of Casein Kinase 1 δ (CK1δ), demonstrating an IC50 of 0.045 μM. This compound is instrumental in research aimed at elucidating the role of CK1δ in various cellular processes, including cell proliferation and circadian rhythm regulation. Its use in biochemical studies provides valuable insights into the modulation of CK1δ-related pathways, making it a critical tool for exploring therapeutic interventions in cancer and other CK1δ-related diseases. -
Casein Kinase 2 Inhibitor
CHX-3107 is a selective inhibitor of Casein Kinase 2 (CK2), a serine/threonine kinase involved in various cellular processes including cell proliferation and apoptosis. By inhibiting CK2, CHX-3107 disrupts downstream signaling pathways, making it a valuable tool for studying CK2's role in cancer biology and other diseases. This compound is utilized in research applications focused on the modulation of kinase activity and its impact on cellular functions. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-19 is a selective inhibitor of casein kinase 1δ, a key enzyme involved in various signaling pathways. This compound exhibits potent inhibitory activity, making it valuable for investigating the molecular mechanisms underlying neurodegenerative diseases, including Alzheimer's disease. It serves as an important tool for researchers exploring therapeutic strategies targeting CK1δ in these conditions. -
Casein Kinase 1d Inhibitor
WAY-606344 is an inhibitor of Casein kinase 1δ, a key regulatory enzyme involved in various cellular processes. This compound is primarily investigated for its potential in Alzheimer's disease research, where modulation of kinase activity may impact neurodegenerative pathways. Its application in studying CK1δ signaling can contribute to understanding disease mechanisms and the development of therapeutic strategies. -
CK-1δ Inhibitor
Casein kinase 1δ-IN-5 is a selective inhibitor of casein kinase 1δ, exhibiting an IC50 of 47 nM. This compound demonstrates neuroprotective and anti-inflammatory effects in vitro, making it a valuable tool for studying neurodegenerative diseases. Its ability to modulate CK-1δ activity provides insights into various cellular processes and potential therapeutic applications in neurological research. -
CK1δ Inhibitor
Casein kinase 1δ-IN-17 is a selective inhibitor of casein kinase 1δ (CK1δ). This compound has shown potential in modulating CK1δ activity, which plays a significant role in various cellular processes. Its primary application is in the research of neurodegenerative disorders, where targeting CK1δ may provide insights into disease mechanisms and therapeutic strategies. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-22 is a potent inhibitor of casein kinase 1δ, an enzyme implicated in various cellular processes. This compound is valuable for investigating the role of casein kinase 1δ in neurodegenerative diseases, including Alzheimer's disease. Its inhibitory activity allows for the exploration of cellular signaling pathways and potential therapeutic strategies targeting CK1δ-related disorders. -
CK1δ Inhibitor
Casein kinase 1δ-IN-18 is a selective inhibitor of casein kinase 1δ (CK1δ). This compound is valuable in research focused on neurodegenerative disorders, where CK1δ plays a critical role in various signaling pathways. By inhibiting CK1δ, Casein kinase 1δ-IN-18 can help elucidate the mechanisms underlying these diseases and aid in the development of potential therapeutic strategies. -
CK1 Inhibitor
CK1δ-IN-9 is a potent inhibitor of casein kinase 1 delta (CK1δ) with an IC50 value of 1.4 nM. This compound also demonstrates inhibitory effects on p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 has favorable pharmacokinetic properties, including 70% oral bioavailability and moderate clearance, making it suitable for research applications in kinase signaling pathways and therapeutic potential in related diseases. -
CK2 Inhibitor
CX-5279 is a selective inhibitor of casein kinase 2 (CK2), exhibiting IC50 values of 2.73 nM for nCK2 and 0.91 nM for CK2α. This compound demonstrates variable sensitivity to specific mutations, with altered IC50 values of 13.8 nM, 12.5 nM, and 23.35 nM for mutations at Val66 and Ile174. Although CX-5279 shows limited inhibitory activity against PIM1 (IC50 = 8.52 μM), it has been reported to possess anti-proliferative effects in various cancer cell lines. This reagent is applicable in research focused on pancreatic cancer and leukemia. -
Casein Kinase 1δ Inhibitor
CK1δ-IN-6 is a selective inhibitor of Casein Kinase 1δ (CK1δ), targeting a key enzyme involved in cellular signaling pathways. Its inhibition has been linked to potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. Research utilizing CK1δ-IN-6 can elucidate the role of CK1δ in cellular processes and its contribution to disease progression, making it a valuable tool for uncovering new insights into Alzheimer's pathology. -
CK II Inhibitor
Tyrphostin AG1112 is a potent inhibitor of casein kinase II (CK II). It demonstrates notable inhibition of the p210bcr-abl tyrosine kinase, with IC50 values of 2 μM for p210bcr-abl, 15 μM for epidermal growth factor receptor (EGFR), and 20 μM for platelet-derived growth factor receptor (PDGFR) in relevant cellular models. This compound is valuable for research investigating cancer signaling pathways and therapeutic interventions targeting kinase activity. -
CK1 Inhibitor
Casein kinase 1δ-IN-31 is a selective inhibitor of casein kinase 1 (CK1), demonstrating potent inhibitory activity against CK1α, CK1δ, and p38α with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, this compound inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM. Casein kinase 1δ-IN-31 is primarily utilized in research applications to explore CK1 signaling pathways and their roles in various cellular processes and diseases. -
Casein Kinase Inhibitor
4,5,6,7-Tetrabromo-1H-benzimidazole is a selective inhibitor of casein kinase 2 (CK2), functioning through an ATP-competitive mechanism. This compound has been shown to effectively inhibit CK2 activity, making it a valuable tool for investigating the role of CK2 in various cellular processes. Its primary applications include studies on cell proliferation, apoptosis, and signal transduction pathways. Researchers may utilize this reagent to explore CK2's involvement in cancer and other disease states. -
CK1 Inhibitor
CK1δ-IN-7 is a selective inhibitor of casein kinase 1δ (CK1δ), a crucial mediator in various cellular signaling pathways. This compound exhibits potent inhibition of CK1δ activity, making it a valuable tool for investigating the role of CK1δ in cellular processes such as circadian rhythms, cellular proliferation, and apoptosis. Researchers can utilize CK1δ-IN-7 in studies related to cancer, neurodegenerative diseases, and other pathophysiological conditions linked to CK1δ signaling dysregulation. -
CK1δ Inhibitor
CK1δ-IN-8 is a selective inhibitor of casein kinase 1 delta (CK1δ), a crucial regulator in various cellular signaling pathways. This compound demonstrates significant potential in Alzheimer's disease research by modulating phosphorylation processes linked to protein aggregation and neurodegeneration. Its application may aid in elucidating the molecular mechanisms underlying Alzheimer's and developing therapeutic strategies. -
CK1δ Inhibitor
Casein kinase 1δ-IN-30 is a selective inhibitor of Casein kinase 1δ (CK1δ). This compound demonstrates significant biological activity in modulating CK1δ activity, making it a valuable tool for investigating neurodegenerative diseases and related pathways. Its application in research can enhance understanding of CK1δ's role in cellular processes and potential therapeutic targets in neurodegeneration. -
CK1δ Inhibitor
CK1δ-IN-5 is a selective inhibitor of Casein kinase 1δ (CK1δ), a key enzyme involved in various cellular processes. This compound plays a significant role in the study of neurodegenerative diseases by modulating upstream signaling pathways that may contribute to neuronal dysfunction. Researchers can utilize CK1δ-IN-5 to explore potential therapeutic targets and elucidate the molecular mechanisms underlying these diseases. -
CK1 Inhibitor
CK1-IN-5 is a selective inhibitor of Casein Kinase 1 (CK1). It has been shown to extend the circadian period by inhibiting the activity of AtCKL3 and AtCKL4. This compound is of significant interest in circadian rhythm research and offers potential applications in studies of sleep disorders and metabolic regulation. -
β-catenin Inhibitor
Zolucatetide is a potent inhibitor of β-catenin, demonstrating an IC50 of less than 50 nM. It disrupts the interaction between β-catenin and the T-cell factor (TCF) transcription factor, leading to inhibited cell proliferation and induced cell cycle arrest in sensitive cell lines. In preclinical studies, Zolucatetide exhibits notable anti-tumor efficacy in xenograft models of colon cancer, specifically in COLO320DM cells with APC and TP53 mutations. This compound is valuable for research focused on colon cancer and related pathways. -
β catenin/BCL9 PPI Inhibitor
ZW4864 is a selective inhibitor of the β-catenin/B-Cell lymphoma 9 (BCL9) protein-protein interaction. It demonstrates potent inhibition with a Ki value of 0.76 μM and an IC50 of 0.87 μM. This compound is valuable for research applications targeting the Wnt signaling pathway in cancer biology, particularly in studies related to tumor progression and development. -
β-catenin Inhibitor
NRX-252262 is a potent β-catenin inhibitor that enhances the interaction between β-catenin and its E3 ligase, SCFβ-TrCP, facilitating the degradation of mutant β-catenin. With an EC50 of 3.8 nM, it serves as a valuable tool for studying the Wnt signaling pathway and its implications in various cancers and developmental processes. This compound is useful in research applications focused on β-catenin dysregulation and therapeutic strategies targeting Wnt-mediated pathways. -
β-Catenin Inhibitor
β-Catenin-IN-2 is a potent inhibitor of β-catenin, a key regulator in the Wnt signaling pathway. This compound demonstrates significant biological activity in various cancer models, particularly in the study of colorectal cancer. Research applications include investigating the role of β-catenin in tumorigenesis and exploring potential therapeutic interventions targeting this pathway. -
β-catenin Inhibitor
β-catenin-IN-3 is a selective inhibitor of β-catenin, targeting a cryptic allosteric modulation site with a binding affinity of K D 54.96 nM. This compound effectively reduces the viability of β-catenin-driven cancer cells by promoting degradation of β-catenin through the proteasome pathway. β-catenin-IN-3 is valuable for research applications focused on cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
Wnt/β-catenin inhibitor
2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research. -
β catenin/BCL9 PPI Inhibitor
ZW4864 free base is a selective inhibitor of the β-catenin/BCL9 protein-protein interaction. It exhibits significant inhibitory activity with a Ki value of 0.76 μM and an IC50 value of 0.87 μM, making it a valuable tool for researching β-catenin signaling pathways. This compound is particularly relevant for studies related to cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin/Tcf PPI Inhibitor
UU-T02 is a selective small-molecule inhibitor targeting the β-catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI), exhibiting a Ki value of 1.36 μM. This compound effectively inhibits canonical Wnt signaling pathways, demonstrating significant potential in suppressing the growth of colorectal cancer cells. Its application in research is valuable for understanding Wnt-related mechanisms in cancer biology and developing therapeutic strategies. -
β-catenin/BCL9 Inhibitor
Antitumor agent-172 is a selective β-catenin/BCL9 inhibitor, demonstrating an IC50 of 3.92 μM and a high binding affinity with a Kd of 82 nM. This compound activates T cells and enhances antigen presentation, thereby exhibiting significant antitumor efficacy. It also displays favorable pharmacokinetic properties in mouse models, making it a valuable tool for cancer research and therapy. -
wnt/β-catenin Inhibitor
Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases. -
β-catenin/BCL9 Inhibitor
Antitumor agent-171 is a potent inhibitor of the β-catenin/BCL9 interaction, demonstrating an IC50 value of 1.61 μM. This compound exhibits a strong binding affinity to β-catenin, with a Kd of 0.63 μM, and effectively inhibits the expression of the axin2 gene with an IC50 of 0.84 μM. Additionally, Antitumor agent-171 reduces cell viability in HCT116 cells at an IC50 of 4.39 μM. Its ability to activate T cells and enhance antigen presentation underscores its potential in antitumor applications, with favorable pharmacokinetic properties observed in mouse models. -
β-catenin/Tcf PPI Inhibitor
UU-T01 is a selective inhibitor of the β-catenin/T-cell factor 4 (Tcf) protein-protein interaction, exhibiting a Ki value of 3.14 µM. This compound directly binds to β-catenin, with a dissociation constant (KD) of 0.531 µM. UU-T01 is valuable in research focused on Wnt signaling pathways and their implications in cellular processes such as proliferation and differentiation, offering potential insights into cancer biology and related disorders. -
β-catenin/Tcf PPI Inhibitor
β-catenin-IN-37 is a selective inhibitor of the β-catenin/T-cell factor (Tcf) protein-protein interaction. This compound effectively disrupts canonical Wnt signaling, exhibiting inhibitory activity against colorectal cancer cell lines SW480 and HCT116, with IC50 values of 20 μM and 31 μM, respectively. β-catenin-IN-37 is valuable for studying Wnt signaling pathways and their implications in cancer research. -
Wnt/β-Catenin Inhibitor
YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation. -
β-catenin/TCF Signaling Inhibitor
CCT031374 hydrobromide is a potent inhibitor of the β-catenin/TCF signaling pathway. It effectively disrupts TCF-dependent transcription of target genes associated with the Wnt signaling cascade. CCT031374 demonstrates significant antitumor activity, making it valuable for research in cancer biology and therapeutic development targeting aberrant Wnt signaling. -
GSK3β Inhibitor
GSK3β-IN-2 is a potent GSK3β inhibitor with an IC50 of 0.35 nM. This compound activates the Wnt/β-catenin signaling pathway, leading to enhanced neurogenesis and neurite outgrowth. Additionally, GSK3β-IN-2 effectively inhibits Aβ-induced tau hyperphosphorylation at Ser396 and reduces neurofibrillary tangle formation. Its efficacy in ameliorating Alzheimer's disease has been demonstrated in zebrafish models, making it a valuable tool for neurological research. -
β-catenin Inhibitor
CGK012 is a selective β-catenin inhibitor that disrupts the Wnt/β-catenin signaling pathway. It effectively inhibits the release of HMGB1 and the transcriptional activity of β-catenin, demonstrating potential therapeutic benefits in sepsis induced by cecal ligation and puncture as well as in multiple myeloma. This compound is valuable for research applications focused on Wnt signaling regulation and its implications in various diseases. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-1 is a selective inhibitor targeting the PTK7/β-catenin signaling pathway, demonstrating an IC50 of 8.9 μM for PTK7/β-catenin and 56.5 μM for p53/MDM2. This compound shows promise in cancer research, particularly in studies examining the modulation of tumorigenic pathways influenced by β-catenin. Its inhibitory effects provide a valuable tool for investigating the role of PTK7 in cancer progression and therapeutic strategies. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-6 is a selective inhibitor of the PTK7/β-catenin interaction, effectively disrupting the Wnt signaling pathway. This compound demonstrates significant anticancer activity, particularly in colorectal cancer (CRC) models, making it a valuable tool for cancer research and therapeutic studies targeting Wnt-related pathways. -
β-catenin Inhibitor
β-catenin-IN-4 is a potent inhibitor of β-catenin, exhibiting an inhibition constant (Ki) of 0.64 μM. This compound effectively decreases the protein expression levels of key oncogenic factors such as cyclin D1 and c-Myc. β-catenin-IN-4 is valuable for research applications focused on cancer biology, particularly in studies investigating the Wnt signaling pathway and its role in tumor progression. -
Wnt/β-catenin Signaling Pathway Inhibitor
Wnt/β-catenin-IN-2 is an inhibitor of the Wnt/β-catenin signaling pathway, displaying an IC50 value of 7.1 μM and a KD value of 2.5 μM. This compound is useful in cancer research, enabling the study of Wnt/β-catenin pathway modulation and its implications in tumorigenesis. Its application can enhance understanding of the mechanistic roles of this pathway in various malignancies. -
β-catenin Inhibitor
β-catenin-IN-6 is an inhibitor of β-catenin, effectively disrupting the canonical Wingless-related integration site signaling pathway. This compound demonstrates significant anti-proliferative effects on human colorectal cancer cells and has been shown to inhibit tumor growth in a β-catenin/RK3E mouse model, making it a valuable reagent for cancer research and therapeutic studies targeting β-catenin signaling pathways. -
β-catenin/BCL9 Complex Inhibitor
E722-2648 is a selective inhibitor of the β-catenin/BCL9 complex, targeting the interaction between these two proteins to inhibit β-catenin-mediated transcriptional activity. This compound demonstrates significant antitumor activity by downregulating the expression of WNT target genes, effectively suppressing tumor growth in colon cancer xenograft and colorectal cancer mouse models. E722-2648 serves as a valuable tool for investigating the molecular mechanisms of colon and colorectal cancers. -
Wnt Inhibitor
PTK7/β-catenin-IN-2 is a potent inhibitor of the PTK7/β-catenin interaction, effectively disrupting Wnt/β-catenin signaling with an IC50 of 5.6 μM. This inhibition impairs cell growth mediated by the Wnt pathway and demonstrates potential anticancer activity. Additionally, PTK7/β-catenin-IN-2 exhibits inhibitory effects on the p53-MDM2 interaction, with an IC50 of 157.1 μM, making it valuable for research focused on cancer therapies and signaling pathway modulation. -
GSK-3 Inhibitor
Laduviglusib dihydrochloride is a selective inhibitor of glycogen synthase kinase-3 (GSK-3), an enzyme involved in numerous cellular processes including glycogen synthesis, cell differentiation, and apoptosis. By inhibiting GSK-3, Laduviglusib dihydrochloride promotes cell survival and has been extensively studied in the context of neurodegenerative diseases, diabetes, and cancer research. This compound serves as a valuable tool for elucidating the role of GSK-3 in various signaling pathways and therapeutic applications. -
Wnt/β-catenin Signal Inhibitor
KP-6 is a polypeptide that acts as a Wnt/β-catenin signaling pathway inhibitor. By inhibiting TGF-β, KP-6 disrupts critical fibrotic signaling pathways in vivo, effectively reducing renal tissue damage and fibrotic progression. This compound holds promise for research focused on chronic kidney disease (CKD) and other fibrosis-related disorders, making it a valuable tool for studying disease mechanisms and potential therapeutic interventions. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-5 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound demonstrates significant inhibition of cell proliferation in HCT 116, SW480, and A549 cell lines, with IC50 values of 3.05 μM, 3.27 μM, and 34.91 μM, respectively. It serves as a valuable tool for research focused on cancer biology and the role of Wnt signaling in tumor development and progression. -
GSK3β Inhibitor
BRD1172 is a selective inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 24 nM. This compound effectively inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells and alleviates the negative regulation of GSK3β on β-catenin degradation and TCF/LEF promoter activity. BRD1172 is applicable in research related to Alzheimer’s disease, cardiac hypertrophy, and various cancers. -
β-catenin:TCF Interaction Inhibitor
β-Catenin inhibitory peptoid targets the β-catenin:TCF interaction, exhibiting an IC50 of 5.44 µM. This compound effectively inhibits Wnt signaling with an IC50 of 0.105 µM and androgen receptor signaling with an IC50 of 1.02 µM in prostate cancer cell lines. The peptoid significantly reduces cell proliferation, making it a valuable tool for research in cancer biology and therapeutic development.
